BRD4 and cancer: Despite the broad presence of BET proteins across thousands of enhancers, inhibition of these proteins (for instance the inhibition of BRD4 by the BET-bromodomain inhibitor JQ1), has led to specific targeting in multiple cancers, revealing cancer dependencies.